Back to results
US 8,278,312 B2Granted
Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes
AssigneeMerck Patent GmbH
InventorsMarkus Klein, Werner Mederski, Christos Tsaklakidis, Norbert Beier
Life of this patent
Estimating the term…
Abstract
Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5, R6 and X7 have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.
Claims4
A compound selected from the following compounds A1 to A27:
- No.
- Structure and/or name
- “A1”
- 2-{2-[3-(2,6-Dimethylphenylamino)imidazo[1,2-a]pyrimidin-
- 2-yl]phenoxy}acetamide
- “A2”
- 2-{2-[3-(2,6-Dimethylphenylamino)-5,7-dimethylimidazo-
- [1,2-a]pyrimidin-2-yl]phenoxy}acetamide
- “A3”
- (2,6-Dichlorophenyl)-{2-[2,4-dimethoxy-6-(5-methylamino-
- 1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}-
- amine
- “A4”
- (2,6-Dichloro-4-fluorophenyl)-{2-[2,4-dimethoxy-6-(5-
- methylamino-1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]-
- pyrimidin-3-yl}amine
- “A5”
- (2,6-Dichlorophenyl)-{2-[2-(5-ethylamino-1,3,4-oxadiazol-2-
- yl)-4,6-dimethoxyphenyl]imidazo[1,2-a]pyrimidin-3-yl}amine
- “A6”
- 5-{2-[3-(2,6-Dichlorophenylamino)imidazo[1,2-a]pyrimidin-
- 2-yl]-3,5-dimethoxyphenyl}-3H-1,3,4-oxadiazol-2-one
- “A7”
- 2-{2-[3-(2,6-Dichlorophenylamino)imidazo[1,2-a]pyrimidin-
- 2-yl]-3-ethylphenoxy}acetamide
- “A8”
- 2-{2-[3-(2,6-Dimethylphenylamino)imidazo[1,2-a]pyrimidin-
- 2-yl]-3-ethylphenoxy}acetamide
- “A9”
- 2-{2-[3-(2,6-Dimethylphenylamino)imidazo[1,2-a]pyrimidin-
- 2-yl]-3-ethyl-5-methoxyphenoxy}acetamide
- “A10”
- 2-{2-[3-(2,6-Dimethylphenylamino)imidazo[1,2-a]pyrimidin-
- 2-yl]-5-methoxy-3-methylphenoxy}acetamide
- “A11”
- {2-[2,4-Dimethoxy-6-(5-methylamino-1,3,4-oxadiazol-2-yl)-
- phenyl]imidazo[1,2-a]pyrimidin-3-yl}-(2,6-dimethylphenyl)-
- amine
- “A12”
- 2-{2-[3-(2,6-Dichlorophenylamino)imidazo[1,2-a]pyrimidin-
- 2-yl]-3-ethyl-5-methoxyphenoxy}acetamide
- “A13”
- (2,6-Dichloro-4-fluorophenyl)-{2-[2-(5-methylamino-1,3,4-
- oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}amine
- “A14”
- (2,6-Dichlorophenyl)-{2-[2-(5-methylamino-1,3,4-oxadiazol-
- 2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}amine
- “A15”
- (2,6-Dichlorophenyl)-{2-[2-(5-ethylamino-1,3,4-oxadiazol-2-
- yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}amine
- “A16”
- {2-[2,4-Dichloro-6-(5-methylamino-1,3,4-oxadiazol-2-yl)-
- phenyl]imidazo[1,2-a]pyrimidin-3-yl}-(2,6-dimethylphenyl)-
- amine
- “A17”
- 2-[3-(2,6-Dichlorophenylamino)imidazo[1,2-a]pyrimidin-2-
- yl]-3,5,N-trimethoxybenzamide
- “A18”
- 2-[3-(2,6-Dichlorophenylamino)imidazo[1,2-a]pyrimidin-2-
- yl]-3,5-dimethoxybenzohydrazide
- “A19”
- {2-[2-Chloro-6-(5-methylamino-1,3,4-oxadiazol-2-yl)phenyl]-
- imidazo[1,2-a]pyrimidin-3-yl}-(2,6-dimethylphenyl)amine
- “A20”
- Methyl 3-chloro-2-[3-(2,6-dimethylphenylamino)imidazo-
- [1,2-a]pyrimidin-2-yl]benzoate
- “A21”
- (2,6-Dimethylphenyl)-{2-[4-methoxy-2-(5-methylamino-
- 1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}-
- amine
- “A22”
- {2-[2-Chloro-6-(5-methylamino-1,3,4-oxadiazol-2-yl)phenyl]-
- imidazo[1,2-a]pyrimidin-3-yl}-(2-chloro-6-methylphenyl)-
- amine
- “A23”
- (2,6-Dichloro-3-methylphenyl)-{2-[2,4-dimethoxy-6-(5-
- methylamino-1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]-
- pyrimidin-3-yl}amine
- “A24”
- 2-[3-(2,6-Dichloro-3-methylphenylamino)imidazo[1,2-a]-
- pyrimidin-2-yl]-N-ethyl-3,5-dimethoxybenzamide
- “A25”
- (3,5-Dimethylisoxazol-4-yl)-{2-[2-(5-methylamino-1,3,4-
- oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}amine
- “A26”
- (2-Chloro-6-methylphenyl)-{2-[2-fluoro-6-(5-methylamino-
- 1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-3-yl}-
- amine
- “A27”
- (4-Fluoro-2,6-dimethylphenyl)-{2-[2-fluoro-6-(5-methyl-
- amino-1,3,4-oxadiazol-2-yl)phenyl]imidazo[1,2-a]pyrimidin-
- 3-yl}amine
- or a pharmaceutically usable salt or stereoisomer thereof, including mixtures thereof in all ratios.
90 more elements
Dependencies are inferred from the claim text.